To investigate the effect of age on Aflibercept (Eylea®) response in macular edema secondary to treatment naive diabetic eyes.


Two hundred eyes of 200 naive patients with macular edema secondary to Diabetes Mellitus were enrolled in this study. The patients in the study were divided into the following four groups according to their ages: group 1 (40-50 years), group 2 (51-60 years), group 3 (61-70 years), and group 4 (>70 years). Three consecutive injections at intervals of 1 month were applied to all diabetic patients. The effectiveness of Aflibercept treatment on macular edema is evaluated via optical coherence tomography (OCT) at baseline and after three loading doses central foveal thickness (CFT) values according to the age groups.


After three consecutive Aflibercept injection, mean reduction of CFT in groups 1, 2, 3, and 4 were -232.8 ± 66.9, -209.3 ± 111.3, -220.8 ± 83.2, and -226.3 ± 100.8 µm, respectively. The reduction of CFT was not different between age groups (p>0.05). Additionally, ages of patients were not correlated with the mean reduction of CFT for the whole study group (r:0.098, p:0.183).


In this study, it was observed that the efficacy of aflibercept treatment did not change with age in diabetic macular edema patients that had not been treated previously.



Kayseri Training and Research Hospital
Kayseri, Turkey
Email: cemalozsaygili@gmail.com
Cell Phone: +905555577040
Work Phone: +903523368884